Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (July 18th Preview)
-
Pancreatic cancer interception vaccine clears key safety and immune readouts
A first-in-human peptide vaccine targeting common mutant KRAS variants showed an early proof of concept for pancreatic cancer interception in high-risk patients. Researchers at Johns Hopkins Kimmel Cancer Center and the Skip Viragh Center for Pancreatic Cancer reported in Cancer Discovery that the mKRAS-VAX regimen was generally safe and stimulated mutant KRAS-specific T-cell responses in 18 of 20 participants (90%) who had hereditary PDAC predisposition and a radiographic pancreatic abnormality (NCT05013216). With a median follow-up of 16.5 months, none of the vaccinated participants developed pancreatic ductal adenocarcinoma. Longitudinal T-cell receptor sequencing demonstrated persistence of vaccine-induced mutant KRAS-specific clonotypes for up to two years, and adverse events were grade 1–2. The work frames vaccination as a strategy to train immune surveillance before detectable transformation. The study matters because prevention/interception in PDAC remains limited by late diagnosis and the difficulty of identifying which precancerous lesions will progress. By focusing on KRAS-driven biology present in most PDACs, the approach aims to translate immune activity into measurable clinical interruption endpoints. Investigators also emphasize that this is an early-stage signal meant to support advancement of mutant KRAS–targeted vaccination strategies for interception rather than treatment after cancer is established.
-
AI-designed CRISPR-like nuclease platform expands editable protein space
Researchers reported in Science a new AI-designed strategy for building functional CRISPR-like nucleases that can rival or outperform natural enzymes. The work describes structure- and evolution-guided design of synthetic, RNA-guided nucleases where activity is preserved while sequences can diverge substantially from reference proteins. The approach is positioned as a way to expand the “CRISPR toolbox” beyond enzymes found in nature. As a test case, the team designed variants for TnpB, a family of CRISPR-Cas12-like nucleases, using an ESM Inverse Folding model (inverse protein-folding) combined with evolution-informed residue constraints to maintain compatibility for guide RNA and DNA recognition. Candidate proteins were then screened for editing activity in cell and nonclinical systems, including plant and animal cells. Separate reporting highlighted a platform from Nobel laureate Jennifer Doudna’s team in Science that generated non-natural TnpB enzymes capable of cutting DNA in multiple biological contexts. Together, the studies point to a workflow where AI proposes enzyme sequences around functional constraints, and lab assays validate whether those designs maintain programmable activity. For biotech, the immediate significance is methodological: if AI-guided nucleases can be reliably engineered with lower off-target behavior or new biochemical properties, the same design loop could be used to tailor editing tools for different therapeutic delivery constraints and safety profiles.
-
DMD gene therapy gets new Phase 3 attempt in Europe after EMA denial
Sarepta announced it is launching an additional Phase 3 trial for Elevidys (delandistrogene moxeparvovec) to address European regulator concerns after the EMA denied marketing authorization last year. Roche, which licensed the therapy, will oversee the new registration-enabling study, designed to generate additional placebo-controlled efficacy and safety data over 72 weeks. The EMA’s 2025 decision cited insufficient evidence in the initial conditional authorization evidence package, including no significant effect on movement abilities at 12 months in the EMBARK program. Sarepta and Roche aim to generate the data they believe meet EMA regulatory requirements for approval in Europe. The company also referenced prior safety scrutiny in the program. Following two patient deaths attributed to acute liver failure in non-ambulatory recipients, the FDA requested a voluntary halt to shipments, and dosing was suspended for non-ambulatory patients in clinical and commercial settings. For the Duchenne gene therapy market, the move keeps Elevidys in play in Europe but highlights the fragility of regulatory pathways when benefit trajectories depend on timepoints, endpoint selection, and placebo-controlled designs.
-
Dimerix buys Mission’s Phase 2-ready kidney injury asset
Dimerix acquired Mission Therapeutics’ acute kidney injury candidate in a deal structured with an upfront payment plus milestone funding. Dimerix will pay $5 million upfront and commit to as much as $287 million in milestones for Mission’s Phase 2-ready program, according to the transaction update. The announcement also notes that Mission appears to be winding down, reflecting how late-stage rescue assets can become scarce when pipelines stall. For Dimerix, the purchase adds a near-term development candidate in a high-need area where successful AKI therapies have historically struggled to reach approval. The structure suggests Dimerix is sharing risk on efficacy and development execution with milestone payments, while securing a program positioned for earlier clinical progression than a discovery-stage asset. In today’s M&A environment, the deal is a clear example of capital reallocations toward assets with defined clinical readiness and regulatory momentum rather than platform-only bets.
-
Juno Bio expands women’s health testing with new funding and a CLIA lab
Juno Bio raised $3.8 million and opened a CLIA-certified sequencing lab in Oakland to scale its vaginal microbiome assay. The company said its test analyzes approximately 10,000 bacteria and fungi and screens for four common sexually transmitted infections, with reported results available through its clinical lab infrastructure. Juno Bio’s funding round was led by investors including Ada Ventures, Artesian, Entrepreneur First, and the Illumina Accelerator, which previously invested in Juno in 2019. The company said it has sold more than 20,000 tests since launch and is using data and capacity to support pharmaceutical R&D partnerships. The assay is currently available in 46 states, with additional expansion planned. The operational step—adding a CLIA lab—matters for biotech developers because it reduces bottlenecks in sample processing and enables larger, more standardized cohorts for microbiome-linked therapeutic studies. For women’s health diagnostics, the move also strengthens the company’s position as a data generator in vaginal ecosystem research, potentially supporting future studies that link microbiome composition to treatment response.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.